Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024, with highest quarterly cartridge sales since 2022 Intelligent Fingerprinting acquisition Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024, with highest quarterly cartridge sales since 2022 Intelligent Fingerprinting acquisition Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results

CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has entered into a subscription agreement with certain new and existing accredited investors to issue and sell an aggregate of 1,249,283 shares of its common stock in a private placement (PIPE) that is expected to result in gross proceeds of approximately $70.0 million, before deducting placement agent fees and estimated offering expenses. The PIPE is expected to close on April 22, 2024, subject to the satisfaction of customary closing conditions. Korro Announces $70 Million Private Placement

Microsoft hat eine neue Studie veröffentlicht, die das präsentiert VASA, ein Framework zum Erstellen realistischer sprechender Gesichter. Die Forscher stellten ihr Modell mit dem Namen vor VASA-1mit dem realistische Videos erstellt werden können, die nur auf einem Standbild und einem Sprachclip basieren. Die Ergebnisse sind beeindruckend und übertreffen alle bisherigen Tools, die generative künstliche Intelligenz […] Die neue KI von Microsoft erhöht das Niveau von Deepfakes gefährlich [Videos]